What medications should be started before intravenous (IV) chemotherapy administration?

Premedications Before IV Chemotherapy

All patients receiving IV chemotherapy should receive antiemetic prophylaxis with a 5-HT3 receptor antagonist plus dexamethasone, with the addition of an NK1 receptor antagonist for highly emetogenic regimens, administered 30 minutes before chemotherapy begins. 1

Antiemetic Regimen Selection Based on Emetogenic Risk

Highly Emetogenic Chemotherapy (HEC)

Administer a 4-drug regimen starting before chemotherapy: 1

• 5-HT3 Receptor Antagonist (choose one): 1

  • Palonosetron 0.25 mg IV (preferred) 1
  • Ondansetron 8-16 mg IV 1
  • Granisetron 1 mg IV or 0.01 mg/kg (max 1 mg) IV 1

• PLUS Dexamethasone 12 mg IV or PO 1

• PLUS NK1 Receptor Antagonist (choose one): 1

  • Aprepitant 125 mg PO 1
  • Fosaprepitant 150 mg IV 1
  • Netupitant 300 mg/palonosetron 0.5 mg PO (single capsule) 1
  • Rolapitant 180 mg PO (use dexamethasone 20 mg instead of 12 mg with this agent) 1

• PLUS Olanzapine 10 mg PO (emerging as category 1 recommendation) 1

Anthracycline Plus Cyclophosphamide Regimens

Use the same 4-drug HEC regimen above 1

• In non-breast cancer populations (e.g., non-Hodgkin lymphoma) already receiving corticosteroids in their chemotherapy regimen, palonosetron without NK1 antagonist plus olanzapine is an acceptable alternative 1

Moderately Emetogenic Chemotherapy (MEC)

Administer a 2-drug regimen: 1

• 5-HT3 Receptor Antagonist (choose one): 1

  • Palonosetron 0.25 mg IV 1
  • Ondansetron 8 mg IV 1
  • Granisetron 1 mg IV or 0.01 mg/kg IV 1

• PLUS Dexamethasone 8 mg IV or PO 1

For carboplatin with AUC ≥4 mg/mL/min, add an NK1 receptor antagonist (making it a 3-drug regimen with dexamethasone 12 mg) 1

Low Emetogenic Risk Chemotherapy

Administer either: 1

• Dexamethasone 8 mg IV or PO 1
• OR a 5-HT3 receptor antagonist (same options as above) 1

Minimal Emetogenic Risk

No routine antiemetic prophylaxis required 1

Timing of Administration

Administer all antiemetics 30 minutes before chemotherapy begins 2, 3

• Ondansetron reaches peak concentration 0.5-2 hours after oral administration, requiring at least 30-minute lead time 3
• Dexamethasone should be given 30 minutes prior to chemotherapy 4
• Aprepitant should be given 1 hour prior to chemotherapy when using oral formulation 4

Critical Dosing Adjustments

When combining aprepitant with dexamethasone, reduce the dexamethasone dose by 50% due to CYP3A4 inhibition 1, 2

• Standard dexamethasone dose without NK1 antagonist: 20 mg 1
• Adjusted dose with aprepitant/fosaprepitant/netupitant: 12 mg 1
• Adjusted dose with rolapitant: 20 mg (no reduction needed as rolapitant does not inhibit CYP3A4) 1

Additional Supportive Medications

Optional Adjuncts (Administer Before Chemotherapy)

• Lorazepam 0.5-2 mg PO/IV for anticipatory nausea or as adjunct (not as monotherapy) 1, 2
• H2 blocker or proton pump inhibitor for patients with epigastric discomfort 1, 2

Hydration for Nephrotoxic Agents

For cisplatin and other nephrotoxic chemotherapy, administer pre-hydration with normal saline to maintain adequate urine output 2

Common Pitfalls to Avoid

Do not use granisetron or any 5-HT3 antagonist as monotherapy for highly emetogenic chemotherapy — combination therapy is mandatory for optimal control 5

Do not use the same drug class for breakthrough nausea — if a patient vomits despite 5-HT3 antagonist prophylaxis, adding more of the same drug will not be effective; switch to a different class like metoclopramide 5, 2

Do not forget to adjust dexamethasone dose downward when using NK1 antagonists (except rolapitant) to avoid excessive steroid exposure 1, 2

Administer antiemetics intravenously if the patient already has active nausea or vomiting, as oral absorption may be compromised 1, 2